Stocks

Vanta Bioscience announces foray into clinical research

| Updated on July 30, 2018

Hyderabad-based Vanta Bioscience, which is in the business of pre-clinical services, announced its foray into clinical research through a 100 per cent subsidiary. The clinical research business will begin contributing to the topline in the last quarter of the current financial year, it said in a statement. The company is projecting to add revenue of ₹250 crore in the fifth year through clinical research services. Major activities covered under clinical services include bio-equivalence studies in healthy human volunteers, patient volunteers, bioanalytical services and clinical trials from Phase I to Phase IV. Shares of Vanta Bioscience gained 3.77 per cent at ₹84.05.

Published on July 30, 2018

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor